Pfizer said Monday that it has started a Phase 2/3 study to test the effectiveness of its oral antiviral drug for preventing infection for those who have been exposed to the coronavirus.
In a statement, Mikael Dolsten, Pfizer’s chief scientific officer, said the company believes “this therapy could help stop the virus early — before it has had a chance to replicate extensively — potentially preventing symptomatic disease in those who have been exposed and inhibiting the onset of infection in others.”
